In adolescents with suspected endometriosis, dienogest 2 mg for 52 weeks was associated with a decrease in lumbar BMD, followed by partial recovery after. By reducing the growth effect of estrogen on the endometrium, dienogest helps to reduce the pelvic pain experienced by women with endometriosis. Dienogest. Endometriosis is a common condition, affecting up to 10% of women. It occurs when endometrial cells proliferate outside the uterus, for example on the ovaries or in the peritoneum. It is associated with symptoms such as chronic pelvic pain, and pain during menstruation and sexual intercourse.


Author: Scot Hettinger
Country: Lithuania
Language: English
Genre: Education
Published: 14 June 2016
Pages: 366
PDF File Size: 30.21 Mb
ePub File Size: 44.2 Mb
ISBN: 477-2-74849-312-3
Downloads: 42397
Price: Free
Uploader: Scot Hettinger


Esmya has been used to treat uterine fibroidsbut its effectiveness as an endometriosis therapy is unknown.

Duphaston, which contains the progestin dydrogesterone, has the ability to reduce pain in endometriosis and avoid pregnancy interruption, but more research is required regarding its use for the disease. Dienogest marketed under the brand name Visannealso a dienogest endometriosis, can inhibit growth and implantation of endometriotic lesions, but its exact dienogest endometriosis is unclear.

Researchers have also never evaluated the recurrence of endometriosis after stopping treatment with Dienogest endometriosis, duphaston or dienogest. This is often treated by discontinuing the COC for a few days and then restarting therapy. GnRH agonists are an established therapy for endometriosis that can be administered via either intramuscular, subcutaneous, or intranasal routes.

Dienogest Treatment Reduces Endometriosis Lesions Better than Duphaston or Esmya, Mouse Study Shows

Although GnRH agonists provide effective pain relief and reduce the progression of endometriotic implants, 29 the hypoestrogenic state that they induce is associated with effects such as accelerated bone mineral density loss, hot flushes, and vaginal dryness.

The optimal regimens for add-back therapy are not yet established. Oral, parenteral, intrauterine, or implantable progestins have been used for decades in the treatment of endometriosis, although for many of these agents there is a lack of supportive evidence from controlled dienogest endometriosis trials.

Dienogest endometriosis data are lacking for most progestins, and there are few comparative data to indicate the benefits of one progestin over another. The progestins that are approved for use in endometriosis vary between countries.

[Full text] Safety and tolerability of dienogest in endometriosis: pooled analysis | IJWH

This medication carries a black box warning concerning possible bone mineral loss. The preparation is not available in Europe. Convincing safety and tolerability data, in combination with proven efficacy, represent key characteristics when choosing an optimal therapy for long-term use in endometriosis.

This paper describes a pooled analysis of safety data from the four European trials that tested dienogest in the approved formulation, with the aim to confirm and further characterize the safety dienogest endometriosis of dienogest in dienogest endometriosis treatment dienogest endometriosis endometriosis.

Methods This pooled analysis derives from four trials in the dienogest European study program.


Details on the study methodologies, including ethical dienogest endometriosis, are described in the individual publications. Participants Of women with confirmed endometriosis who were included in the four dienogest endometriosis, were treated with dienogest 2 mg once daily for study periods between 12 weeks and 65 dienogest endometriosis.

The criteria for the assessment of safety and tolerability in these trials are described in the following paragraphs on adverse events and laboratory tests.


Adverse events and adverse drug reactions Adverse events AEs were defined as any unfavorable and unintended sign, symptom, or disease occurring with the use of study medication.

AEs were described using the Medical Dictionary for Regulatory Activities or else were dienogest endometriosis in the present study to Medical Dictionary for Regulatory Activities terms to permit data pooling. The intensity of AEs was categorized as mild, moderate, or severe.

AEs that were considered by investigators to dienogest endometriosis at least potentially related to study medication were described as dienogest endometriosis drug reactions ADRs.

New drugs: Dienogest

Premature discontinuation rates due to AEs were also included for analysis, as an index of overall tolerability. Laboratory tests Safety laboratory tests included hematology, blood chemistry, liver enzyme, glucose metabolism glycated hemoglobinlipid, and hormone assessments, which were determined at minimum at the baseline visit and the end of treatment in all studies.

Vital signs Systolic and diastolic dienogest endometriosis pressure and heart rate were measured at baseline and at every scheduled visit in all studies, with the exception of the dose-ranging trial, which measured blood pressure alone. Body weight Body weight was measured at minimum at baseline visit and dienogest endometriosis the end of treatment in all studies.

Gynecologic examination Gynecologic dienogest endometriosis were performed at minimum at baseline visit and at the end of treatment in all studies.